Weight loss drugs not a threat to Nestle biz: CEO Mark Schneider
Nestle CEO Mark Schneider has defended its strategy of building a lower-calorie product portfolio, stating that the threat of GLP-1 weight-loss drugs is less significant. The company now generates half of its revenue from coffee, pet care, and vitamins...
